Skip to main navigation
  • Investors

    Investors

    • IR Information
    • Stock Information
    • Press Releases
    • Events & Webcasts
    • Presentations
    • Enhanced SEC Filings
    • Analyst Coverage
    • Corporate Governance
      • Management
      • Board of Directors
      • Documents & Charters
      • Committee Composition
    • Investor FAQs
    • IRS Form 8937
    • Investor Contacts
  • News
    • Press Releases
    • Events
  • Publications
    • Manuscripts and Presentations
  • Careers
  • LinkedIn
  • Twitter
  • Our Focus
    • Why Rare?
    • Why Neuropsychiatric Disorders?
    • Why Cannabinoids?
    • Why pharmaceutical manufacturing?
  • Our Pipeline
    • ZYN002 CBD Gel
    • CONNECT-FX Trial
    • Early Access to Medicine
  • Clinical Trials
  • Our Team
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Patient Resources
    • FXS
    • ASD
    • 22q
    • DEE
    • Epilepsy

Corporate Governance - Committee Composition

Corporate Governance

  • Highlights
  • Management
  • Committee Composition
Nominations and Corporate Governance Committee Audit Committee Compensation Committee
John Bulter Nominations and Corporate Governance Committee Compensation Committee
Warren D. Cooper, MB, BS, BSc, MFPM Nominations and Corporate Governance Committee Audit Committee
William J. Federici Audit Committee
Daniel L. Kisner, M.D. Compensation Committee
Kenneth I. Moch Audit Committee Compensation Committee
Pamela Stephenson Nominations and Corporate Governance Committee
= Chairperson = Member

Investor Relations

  • Investor Relations
    • IR Information
    • Stock Information
    • Press Releases
    • Events & Webcasts
    • Presentations
    • Enhanced SEC Filings
    • Analyst Coverage
    • Corporate Governance
      • Management
      • Board of Directors
      • Documents & Charters
      • Committee Composition
    • Investor FAQs
    • IRS Form 8937
    • Investor Contacts

Investor Tools

  • Print Page
  • RSS Feeds
  • E-mail Alerts
  • Privacy Policy
  • Terms of Use
  • Contact Us

© 2023 Zynerba Pharmaceuticals, Inc. All rights reserved.

zynerba inverted logo

80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
484.581.7505